Erasca, Inc. logo

Erasca, Inc.

NASDAQ:ERAS

Overview | Financials
Company Name Erasca, Inc.
Symbol ERAS
Currency USD
Price 2.97
Market Cap 771,739,650
Dividend Yield 0%
52-week-range 1.51 - 3.1
Industry Biotechnology
Sector Healthcare
CEO Dr. Jonathan E. Lim M.D.
Website https://www.erasca.com

An error occurred while fetching data.

About Erasca, Inc.

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor

Related Stocks

Design Therapeutics, Inc. logo

Design Therapeutics, Inc.

DSGN

4.36 USD

Cross Country Healthcare, Inc. logo

Cross Country Healthcare, Inc.

CCRN

13.79 USD

POINT Biopharma Global Inc. logo

POINT Biopharma Global Inc.

PNT

12.5 USD

uniQure N.V. logo

uniQure N.V.

QURE

8.72 USD

SIGA Technologies, Inc. logo

SIGA Technologies, Inc.

SIGA

8.72 USD

Replimune Group, Inc. logo

Replimune Group, Inc.

REPL

10.36 USD

The Oncology Institute, Inc. logo

The Oncology Institute, Inc.

TOI

0.47 USD

Financials

Numbers are in millions USD

Numbers are in millions USD